Huifang Li

Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS disorders such as epilepsy, drug addiction and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations (2014-2016), 2017 CBA Annual Conference Chair and 2017-2018 Vice President.